Literature DB >> 10745050

Increased cerebrospinal fluid glutamine levels in depressed patients.

J Levine1, K Panchalingam, A Rapoport, S Gershon, R J McClure, J W Pettegrew.   

Abstract

BACKGROUND: There is increasing evidence for an association between alterations of brain glutamatergic neurotransmission and the pathophysiology of affective disorders.
METHODS: We studied the association between cerebrospinal fluid (CSF) metabolites, including glutamine, in unipolar and bipolar depressed patients versus control subjects using a proton magnetic resonance spectroscopy technique. Cerebrospinal fluid samples were obtained from 18 hospitalized patients with acute unmedicated severe depression without medical problems and compared with those of 22 control subjects.
RESULTS: Compared with the control group, the depressed patient group had significantly higher CSF glutamine concentrations, which correlated positively with CSF magnesium levels.
CONCLUSIONS: These findings suggest an abnormality of the brain glial-neuronal glutamine/glutamate cycle associated with N-methyl-D-aspartate receptor systems in patients with depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745050     DOI: 10.1016/s0006-3223(99)00284-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  71 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

3.  Glutamate level detection by magnetic resonance spectroscopy in patients with post-stroke depression.

Authors:  Xuan Wang; Yue-Hua Li; Ming-Hua Li; Jing Lu; Jun-Gong Zhao; Xiao-Jiang Sun; Bin Zhang; Jian-Lin Ye
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-18       Impact factor: 5.270

Review 4.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

5.  Metabolomic differences in heart failure patients with and without major depression.

Authors:  David C Steffens; K Ranga R Krishnan; Edward D Karoly; Matthew W Mitchell; Christopher M O'Connor; Rima Kaddurah-Daouk
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-01-25       Impact factor: 2.680

Review 6.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 7.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

8.  Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome.

Authors:  M R Pranzatelli; E D Tate; J M Crowley; B Toennies; M Creer
Journal:  Neuropediatrics       Date:  2008-11-07       Impact factor: 1.947

Review 9.  The As and Ds of stress: metabolic, morphological and behavioral consequences.

Authors:  Lawrence P Reagan; Claudia A Grillo; Gerado G Piroli
Journal:  Eur J Pharmacol       Date:  2008-02-26       Impact factor: 4.432

10.  Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.